We and others have shown that the combination of HDAC and proteasomal pathway inhibitors synergistically induces glioma cell death, suggesting the appeal of combination therapeutics to maximize treatment response [17, 26, 27, 28]. This evidence concerns the gene HDAC9 and glioma.